AGP Picks
View all

Kevan Shokat wins $1 million Stephenson Global Prize after KRAS breakthrough helps fuel FDA-approved pancreatic cancer drug

Oct. 29, 2026
Kevan Shokat wins $1 million Stephenson Global Prize after KRAS breakthrough helps fuel FDA-approved pancreatic cancer drug
By AI, Created 13:30 UTC, Oct 29, 2026, AGP -

Kevan M. Shokat, PhD, has been named the 2026 Stephenson Global Prize laureate for research that helped crack KRAS, a long-elusive cancer target. The honor comes as FDA approval of daraxonrasib gives metastatic pancreatic cancer patients a new treatment option linked to his discovery work.

Why it matters: - Kevan M. Shokat’s research helped turn KRAS from a target long viewed as untouchable into the basis for a new class of pancreatic cancer therapies. - The award recognizes work that is now reaching patients through daraxonrasib, the first broad RAS-targeted medicine approved for metastatic pancreatic cancer. - Pancreatic cancer remains the third leading cause of cancer-related death in the U.S. and has a five-year survival rate of 13%. - New therapies matter because the disease has long had few effective treatment options and low federal research support relative to its death toll.

What happened: - The Stephenson Global Pancreatic Cancer Research Institute named Shokat the 2026 Stephenson Global Prize laureate and awarded him $1 million. - The honor was presented during the Stephenson Global Prize Ceremony at the AACR Advances in Pancreatic Cancer Research Special Conference in San Diego. - The FDA approved daraxonrasib (Rasonque), developed by Revolution Medicines, for adults with metastatic pancreatic adenocarcinoma. - Shokat is the second recipient of the prize, following Frank McCormick, PhD, FRS, FAACR, in 2025.

The details: - In 2013, Shokat discovered a previously hidden pocket on the surface of mutated RAS, showing that the protein could be bound and disabled by a small molecule. - The finding helped overturn the long-held view that KRAS was “undruggable.” - Shokat co-founded Revolution Medicines and later served as an academic co-founder and scientific adviser. - Revolution Medicines built its RAS(ON) platform from that scientific foundation and ultimately engineered daraxonrasib. - In the pivotal clinical trial supporting approval, daraxonrasib improved median overall survival to 13.2 months versus 6.7 months with standard chemotherapy. - KRAS mutations drive more than 90% of pancreatic cancers. - Shokat was elected a Fellow of the AACR Academy in 2023 for discoveries in chemical genetics, including work on covalent inhibitors targeting KRAS G12C. - SGPCRI was established through a $150 million gift from A. Emmet Stephenson Jr. and Tessa Stephenson Brand, in partnership with City of Hope. - The institute says its mission is to advance early detection, treatments and high-impact research through innovation, collaboration and strategic funding. - The institute directs readers to more information and lists LinkedIn and X as follow options.

Between the lines: - The prize is not just a lifetime-achievement award; it is a signal that one of the field’s hardest scientific problems has begun producing clinical returns. - The sequence from basic discovery to FDA approval shows how long-horizon academic science can become a commercial therapy when industry and research institutions stay aligned. - The recognition also underscores how philanthropic funding is being positioned as a backstop for high-risk cancer research amid uncertainty in federal support. - McCormick’s earlier work helped establish KRAS as a central cancer driver, while his encouragement helped set the stage for Shokat’s direct targeting approach.

What's next: - SGPCRI said it will continue investing in ambitious pancreatic cancer research aimed at earlier detection and better treatments. - The broader RAS-targeted drug field is likely to keep expanding as researchers build on Shokat’s structural insight. - The clinical impact of daraxonrasib will be watched closely as more patients receive the therapy in real-world practice.

The bottom line: - Shokat’s prize marks a rare moment when a basic-science breakthrough, a new cancer drug and a survival benefit all converge in the same story.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Online Network

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.